- Home
- MHO vs RNA Comparison
MHO vs RNA Comparison
Compare MHO & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHO | RNA |
|---|---|---|
| Founded | 1976 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | 1986 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MHO | RNA |
|---|---|---|
| Price | $135.29 | $71.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | ★ $153.00 | $69.26 |
| AVG Volume (30 Days) | 192.3K | ★ 2.4M |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.05 | N/A |
| Revenue | ★ $4,475,753,000.00 | $20,868,000.00 |
| Revenue This Year | N/A | $64.11 |
| Revenue Next Year | N/A | $37.25 |
| P/E Ratio | $7.96 | ★ N/A |
| Revenue Growth | 4.77 | ★ 106.27 |
| 52 Week Low | $100.22 | $21.51 |
| 52 Week High | $158.92 | $71.86 |
Technical Indicators
Market Signals| Indicator | MHO | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 76.01 |
| Support Level | $127.87 | $71.18 |
| Resistance Level | $137.10 | $71.79 |
| Average True Range (ATR) | 4.14 | 0.37 |
| MACD | 0.29 | -0.62 |
| Stochastic Oscillator | 59.36 | 99.16 |
Price Performance
Historical ComparisonAbout MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.